XML 71 R56.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - Purchase Price Allocation (Details) - USD ($)
$ in Thousands
7 Months Ended
Dec. 31, 2020
May 20, 2020
Jan. 31, 2019
13% Senior Secured Note due 2024 | Senior Notes      
Adjustments to Purchase Price Allocation to Fair Value      
Interest rate 13.00% 13.00%  
13% Senior Secured Note due 2024 | Senior Notes | Zyla Life Sciences      
Adjustments to Purchase Price Allocation to Fair Value      
Interest rate     13.00%
Zyla Life Sciences      
Purchase Price Allocation to Fair Value      
Cash $ 7,585 $ 7,585  
Accounts receivable 23,133 23,133  
Inventories 14,261 26,742  
Property and equipment 1,496 4,512  
Intangible assets 193,400 160,900  
Other assets 7,665 9,629  
Total identifiable assets acquired 247,540 232,501  
Accounts payable 21,574 21,574  
Accrued rebates, returns and discounts 33,254 33,254  
Other accrued liabilities 23,858 15,434  
Contingent consideration 39,900 29,400  
Debt 111,300 111,900  
Total liabilities assumed 229,886 211,562  
Net identifiable assets acquired 17,654 20,939  
Goodwill 17,432 14,147  
Net assets acquired 35,086 $ 35,086  
Adjustments to Purchase Price Allocation to Fair Value      
Inventories (12,481)    
Property and equipment (3,016)    
Intangible assets 32,500    
Other assets (1,964)    
Total identifiable assets acquired 15,039    
Other accrued liabilities 8,424    
Contingent consideration 10,500    
Debt (600)    
Total liabilities assumed 18,324    
Net identifiable assets acquired (3,285)    
Goodwill 3,285    
Zyla Life Sciences | Promissory note      
Purchase Price Allocation to Fair Value      
Debt 3,000    
Zyla Life Sciences | Credit agreement      
Purchase Price Allocation to Fair Value      
Debt 10,000    
Zyla Life Sciences | 13% Senior Secured Note due 2024 | Senior Notes      
Purchase Price Allocation to Fair Value      
Debt 95,000    
Zyla Life Sciences | Royalty rights obligation | Senior Notes      
Purchase Price Allocation to Fair Value      
Debt $ 3,300